Zhao Yun, Tang Ying, Wang Qi Yao, Li Jia
Department of Glaucoma, The Second Hospital of Jilin University, Changchun, China.
Front Immunol. 2025 Feb 4;16:1515768. doi: 10.3389/fimmu.2025.1515768. eCollection 2025.
With the consistent occurrence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, the prevalence of various ocular complications has increased over time. SARS-CoV-2 infection has been shown to have neurotropism and therefore to lead to not only peripheral inflammatory responses but also neuroinflammation. Because the receptor for SARS-CoV-2, angiotensin-converting enzyme 2 (ACE2), can be found in many intraocular tissues, coronavirus disease 2019 (COVID-19) may also contribute to persistent intraocular neuroinflammation, microcirculation dysfunction and ocular symptoms. Increased awareness of neuroinflammation and future research on interventional strategies for SARS-CoV-2 infection are important for improving long-term outcomes, reducing disease burden, and improving quality of life. Therefore, the aim of this review is to focus on SARS-CoV-2 infection and intraocular neuroinflammation and to discuss current evidence and future perspectives, especially possible connections between conditions and potential treatment strategies.
随着严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的持续发生，各种眼部并发症的患病率随时间有所增加。已证明SARS-CoV-2感染具有嗜神经性，因此不仅会导致外周炎症反应，还会引发神经炎症。由于在许多眼内组织中都能发现SARS-CoV-2的受体血管紧张素转换酶2（ACE2），2019冠状病毒病（COVID-19）也可能导致持续性眼内神经炎症、微循环功能障碍和眼部症状。提高对神经炎症的认识以及未来对SARS-CoV-2感染干预策略的研究对于改善长期预后、减轻疾病负担和提高生活质量至关重要。因此，本综述的目的是聚焦于SARS-CoV-2感染和眼内神经炎症，并讨论当前的证据和未来的前景，特别是相关病症之间可能的联系以及潜在的治疗策略。
